Total flavonoid fraction of the Herba epimedii extract suppresses urinary calcium excretion and improves bone properties in ovariectomised mice
- 6 September 2010
- journal article
- research article
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 105 (2) , 180-189
Abstract
Flavonoids are the active components of Herba epimedii (HEP), a commonly used herb for the management of osteoporosis in China over the centuries. The present study aims to characterise the in vivo effects of its total flavonoid (TF) fraction on bone properties and mineral metabolism as well as to study the mechanism involved in achieving its protective effects against ovariectomy (OVX)-induced bone loss. TF suppressed OVX-induced increase in urinary Ca excretion as well as loss of bone mass and strength at the distal femur in mice in a dose-dependent manner. The changes in urinary Ca excretion were inversely correlated with the expressions of renal Ca transport protein (CaBP-28K) and vitamin D receptor mRNA in OVX mice. TF (100 μg/g) treatment prevented the deterioration of trabecular bone microarchitecture induced by OVX in mice. In addition, TF treatment increased the expression of type I collagen and osteocalcin mRNA and the ratio of osteoprotegerin/receptor activator of NF-κB ligand mRNA, and suppressed the increase in IL-6 mRNA induced by OVX in the femur of mice. The present results indicate that the optimal dosage of the TF fraction of HEP for the improvement of bone properties and mineral metabolism in OVX mice was between 50 and 100 μg/g. Mechanistic studies indicated that TF might increase renal Ca reabsorption, stimulate the process of osteoblast formation as well as suppress the process of osteoclastogenesis in OVX mice.Keywords
This publication has 23 references indexed in Scilit:
- Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor‐dependent osteoblastic functions in UMR 106 cellsBritish Journal of Pharmacology, 2010
- Dosing effects of an antiosteoporosis herbal formula – a preclinical investigation using a rat modelPhytotherapy Research, 2007
- Icaritin and its glycosides enhance osteoblastic, but suppress osteoclastic, differentiation and activity in vitroLife Sciences, 2007
- The HRT misuse and osteoporosis epidemic: a possible future scenarioClimacteric, 2007
- Patient Adherence to Osteoporosis MedicationsDrugs & Aging, 2007
- Calbindin‐D28K dynamically controls TRPV5‐mediated Ca2+ transportThe EMBO Journal, 2006
- Breast cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6Science, 1992
- EFFECTS OF NATURAL AND ARTIFICIAL MENOPAUSE ON PLASMA AND URINARY CALCIUM AND PHOSPHORUSThe Lancet, 1967